The primary goal of antiretroviral therapy (ART) is to reduce<unk> -associated morbidity and mortality. This goal is best accomplished by using highly-active ART to maximally inhibit<unk>  replication, as defined by achievement and maintenance of plasma<unk>  RNA (viral load) below detectable levels, restoration of normal CD4 cell count, and prevention of transmission of the disease. Major classes of agents used in the treatment of<unk>  are: Non-nucleoside reverse transcriptase inhibitors (NNRTIs), nucleoside reverse transcriptase inhibitors (NRTIs), protease inhibitors (PIs), fusion inhibitors, CCR5 antagonists, and integrase inhibitors. All regimens are combinations of at least 3 agents, preferably with 2 NRTIs.  Durable viral suppression improves immune function and quality of life, lowers the risk of both<unk> -defining and non-AIDS-defining complications, and prolongs life. Based on emerging evidence, additional benefits of ART include a reduction in<unk> -associated inflammation and its associated complications.
HIV AIDS medical therapy
Hepatitis C medical therapy
Hepatitis B medical therapy
Hepatitis D medical therapy
HIV associated nephropathy medical therapy
Syphilis medical therapy
Neurosyphilis medical therapy
Hepatitis E medical therapy